Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tegio consolidation therapy in high-risk nasopharyngeal carcinoma
NCT03904225Phase 2Unknown
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Dec 2018
- Primary completion
- Dec 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of tegafur + gimeracil + oteracil in nasopharyngeal carcinoma (NPC) (2 arms), sponsored by Zhejiang Cancer Hospital. Primary endpoint: Distant Failure-Free Survival at 36 months. Status: unknown.
02
Drugs
tegafur + gimeracil + oteracil
03
Conditions
nasopharyngeal carcinoma (NPC)
Beyond the preview
Go deeper on NCT03904225.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03904225.